Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nortran Pharmaceutical -NRT.V -- Ignore unavailable to you. Want to Upgrade?

To: SOROS who wrote (873)	6/13/1998 9:37:00 PM
From: Edward W. Richmond	Respond to of 1185

Soros, I agree that another step has been taken. When I review the drugs under investigation and speculate on where Nortran could realistically be in 24 months, I see a very positive picture. However, it looks like Vancouver companies are in for a great deal of volatility. In the long term, the ups and downs don't really have much significance. Glad to be long on Nortran. Regards, Ed

To: SOROS who wrote (873)	6/14/1998 1:15:00 PM
From: Ms. Forthright	Read Replies (1) \| Respond to of 1185

SOROS, it is my understanding that this compound has already passed all clinical studies for another indication. Adverse effect profile was excellent, however, the drug was no more effective than others currently on the market. Unfortunately, for each indication new clinical trials must be performed, we already know though that this drug is very well tolerated. I believe that in the earlier clinical trials subjects who happened to have a cough noticed that it went away with this drug. This is pretty neat since at this time there are no good cough suppressants. Dextromethorphan is the most common antitussive. This is what you will find in most OTC formulations. It doesn't work much better than placebo. Codeine and other narcotics are a little more efficacious, but they do have significant side effects and abuse potential. Inhaled steroids can work nicely in some patients, however, they tend to be pricey and are somewhat cumbersome to use. The big market here is for over the counter, this is already huge and available compounds are not nearly as effective as that offered by Nortran. Don't worry with all the developments happening at Nortran its stock will inevitably perform very nicely (then we will kick ourselves for not having bought more at this level)!